Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study - PubMed (original) (raw)

Comparative Study

doi: 10.1016/j.jhep.2013.07.005. Epub 2013 Jul 10.

Georgia Vourli, George Dalekos, Themistoclis Vasiliadis, Nina Manolaki, Athina Hounta, Sotirios Koutsounas, Irini Vafiadis, Georgia Nikolopoulou, Gregory Giannoulis, George Germanidis, George Papatheodoridis, Giota Touloumi

Affiliations

Comparative Study

Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study

Emanuel K Manesis et al. J Hepatol. 2013 Nov.

Abstract

Background & aims: Hepatitis D virus (HDV) has decreased in Europe, but recent reports indicate a rising trend. We report the epidemiological changes, clinical progress, and effect of treatment on the natural course of HDV infection in Greece during the last 13 years.

Methods: Prospective data were extracted from the HepNet.Greece Cohort-Study.

Results: Since 1997, 4673 chronic HBV (CHB) cases (4527 adults, 146 children) have been followed prospectively. Two thousand one hundred thirty-seven patients were tested for anti-HDV [101 (4.7%) positive]. Anti-HDV testing in Greece decreased significantly (57.0% before 2003, 35.3% thereafter; p<0.001). Anti-HDV prevalence among HBsAg-positives was 4.2%; lower in native Greeks (2.8%) than in immigrants (7.5%) or in children (15.3%; p<0.001). Within 2.3 years of follow-up, HDV occurred in 11/2047 HBsAg-positive patients (2.2 new delta-infected adults and 8.7 children per 1000 HBsAg-positive annually). HDV-positive compared to CHB adults were younger (p=0.035) and had more active and advanced disease at baseline, as indicated by laboratory indices and the higher prevalence of cirrhosis at younger age. During a 4.2-year median observation, significantly more anti-HDV-positive than CHB adults developed a liver-related first event (20.0% vs. 8.5%, p Log-rank=0.014).Treatment was received by 46/90 (51.1%) patients, 40 of them interferon-based. In multivariable analysis, interferon significantly decreased disease progression in HDV-positive patients [HR=0.14 (95% CI: 0.02-0.86; p=0.033)].

Conclusions: In Greece, HDV serology is currently tested in only one-third of HBsAg-positive patients. HDV prevalence is lower in native Greeks compared to immigrants, who may contribute >50% of the HDV infection burden in Greece. Data show that HDV infection is a rapidly progressive disease, but interferon-based treatment may alter its course.

Keywords: ALT; Anti-HDV testing in HBsAg-positive patients; CHBe+; CHBe-; CHD; CI; Chronic HDV infection; Greece; HBV; HBV DNA; HBeAg; HBeAg-negative chronic hepatitis B; HBeAg-positive chronic hepatitis B; HBsAg; HCC; HDV; HDV RNA; HDV-PNALT; HDV-clinical course; HDV-epidemiology; HDV-infected patients with persistently normal ALT; HIV; IFN; IQR; IU/L; IU/ml; IVDU; NA(s); Treatment of HDV; alanine aminotransferase; alpha interferon (both recombinant or pegylated distinguished when necessary); chronic hepatitis D; confidence interval; hepatitis B surface antigen; hepatitis B viral DNA; hepatitis B virus; hepatitis B “e” antigen; hepatitis delta viral RNA; hepatitis delta virus; hepatocellular carcinoma; human immunodeficiency virus; illicit intravenous drug use(r); international units per liter; international units per milliliter; interquartile range; nucleos(t)ide analogue(s).

Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources